GCP
NVNO

GSA Capital Partners’s enVVeno Medical NVNO Stock Holding History

GSA Capital Partners’s Portfolio NVNO Stock Details NVNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,674
Closed -$64K – 2035
2025
Q4 		$64K Buy
5,674
+5,291
+1,381% +$103K 0.01% 1562
2025
Q3 		$12K Buy
+383
New +$39.1K ﹤0.01% 1593

Other funds holding NVNO

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

GSA Capital Partners's NVNO Position: Q1 2026 in Review

GSA Capital Partners sold out of enVVeno Medical (NVNO) in Q1 2026, closing a stake of 5,674 shares — an estimated $64K sold.

GSA Capital Partners first reported a position in NVNO in Q3 2025 and held it in 2 quarters. The position peaked at $64K in Q4 2025. 17 funds tracked by Wall St. Rank hold NVNO as of Q1 2026.

  • GSA Capital Partners reported no remaining enVVeno Medical position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 5,674 enVVeno Medical shares in Q1 2026, an estimated $64K.
  • GSA Capital Partners first reported a position in enVVeno Medical in Q3 2025 and held it in 2 quarters.
  • GSA Capital Partners's enVVeno Medical position peaked at $64K in Q4 2025.
  • 17 funds tracked by Wall St. Rank held enVVeno Medical as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.